Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI-Reference-Cited by-同舟云学术

Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI

Published:2021-12 Issue: Volume:111 Page:106674
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Ma Chen-En,Ghosh Sunita,Leyshon Catherine,Blosser Nikki,Dersch-Mills Deonne,Jupp Jennifer,Savoie Lynn,Liew Elena,Jamani Kareem^ORCID

Funder

Alberta Health Services

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference24 articles.

1. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring;Jabbour;Am. J. Hematol.,2020

2. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology;Radich;J. Compr. Canc. Netw.,2018

3. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O’Brien;N. Engl. J. Med.,2003

4. Final 5-Year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial;Cortes;J. Clin. Oncol.,2016

5. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial;Hochhaus;Leukemia,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance;Leukemia;2024-02-29

2. Real-world Management of CML: Outcomes and Treatment Patterns;Current Hematologic Malignancy Reports;2023-07-03

3. Dasatinib/nilotinib;Reactions Weekly;2022-11-12